Because of their extensive expression of PRR, these DC are able to recognize tumor-derived PAMPs and show enhanced presentation of these antigens to tumor-specific T-cells, thereby decreasing the expression of tolerogenic markers PD-L1 [52,53]. The gene discussed is CD274; the disease is neoplasm.